Kari Wisinski, MD

Great @bigtencrc.bsky.social summit today. Advancing cancer research collaboration across the growing BigTen (now 18!) team. Honoring colleagues including Dr. Bailey and meeting new members.

We are delighted to announce two key leadership promotions, elevating staff who have played an integral role in strengthening clinical research and innovating new patient care across cancer… | UW Carb... We are delighted to announce two key leadership promotions, elevating staff who have played an integral role in strengthening clinical research and innovating new patient care across cancer types.   K...

Excited by this new opportunity at the Carbone Cancer Center @uwhealth.bsky.social and know Dr. Uboha will be an excellent leader of our clinical trials program! www.linkedin.com/feed/update/...

Look at Darian, research coordinator @uw Carbone presenting this trial

Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers - Breast Cancer Research and Treatment Purpose Metastatic triple negative breast cancer has a poor prognosis with limited targeted treatment options. In preclinical studies PI3K inhibition led to increased DNA damage and subsequent sensiti...

Excited to see this BigTen met TNBC study @bigtenplus.bsky.social published. Although primary endpt not met, addressed an important question and some interesting observations for future. link.springer.com/article/10.1...

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy | NEJM The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, but whether it is also beneficial for patie...

In women with node-positive breast cancer whose nodes became free of disease after neoadjuvant therapy, regional nodal irradiation did not reduce breast cancer recurrence or improve survival. Full results from a phase 3 trial: nej.md/4dM6LjD

#MedSky #Oncology

Key take homes for #breastcancer at #ASCO25 (3)
*Triplet PI3k (Inavo)+fulv+palbo improved OS in MBC in those with early progression on adjuvant AI (need early NGS for PIK3CA
*TDXd (plus pertuz) improves PFS in 1L HER2+ MBC. Will watch for PFS2/OS in future. Key ? is how to integrate PATINA in ER+

Key take homes for #breastcancer at #ASCO25 (2)
*1st PROTAC (vepdeg) improves PFS in mESR1 MBC
*Monitoring ctDNA for ESR1 mutations in MBC w early change to SERD (cami) improves PFS, longer term outcomes important
*Dose escalation of abema improves tolerance (TRADE)

Key take homes for #breastcancer at #ASCO25 (1)
*OFS/AI in high risk preM women reduced recurrence. OS not met (at 15 yrs) but w/o detriment to non-cancer OS
*Vasomotor AEs from ET effectively reduced w elinzanetant
*Select stage 1-3 HER2+ BC may not need carbo
*SG + pembro is a new 1L TNBC option

What a great surprise from the breast med onc clinic team today! Made my day-so thoughtful.

Pursuing a vaccine to treat glioblastoma - School of Medicine and Public Health Dr. Mahua Dey is an associate professor in the Department of Neurological Surgery and the director of the surgical neuro-oncology program in the University of Wisconsin School of Medicine and Public Health. She specializes in the surgical management of both benign and malignant brain tumors.

Meet Mahua Dey — neurosurgeon, scientist and innovator at @uwmadison.bsky.social. She's leading the charge against glioblastoma, one of the deadliest brain cancers. Her lab's personalized therapeutic vaccine, GIFT-7, has shown remarkable success in preclinical trials.

Former Univ of Wisconsin heme/onc fellow!!

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%)...

Just talked about these results with 2 pts in 2 weeks. Improved outcomes with ET in ERlow breast cancer, unless pCR to Neoadj chemo. ascopubs.org/doi/10.1200/...

April 11: The Week in Cancer News | Cancer Today NIH layoffs delay research benefiting cancer patients, and celebrity cancer news is often missing important information.

NIH layoffs delay research benefiting cancer patients, and celebrity cancer news is often missing important information, and more news from Cancer Today magazine: www.cancertodaymag.org/cancer-talk/...

Loving the @uwhealth.bsky.social Carbone Cancer Center Community day for @uwbadgers.bsky.social science days. Attempted Brain surgery (sticking to med onc), attended panel on working w research advocates, ice cream and more!

US map via scienceimpacts.org visualization of economic loss due to IDC cuts to 15% as part of Feb 7, 2025 executive order, with shading denoting intensity of cuts.

Working with an interdisciplinary team, we have developed a website to communicate how the White House's proposed cuts to health research would cause losses of $16B and 68,500 jobs.

Find out how your community may be impacted.

Explore more at SCIMaP: scienceimpacts.org

a 🧵

The resignation letter should be seen by all. A reminder to keep speaking up/advocating for science.

Peter Marks, top US vaccine official, forced to resign, reports say In his resignation letter, Peter Marks said his new boss, Robert F Kennedy Jr, favoured

Peter Marks forced to resign www.bbc.co.uk/news/article...

Had a great team dinner with these amazing @uwhealth.bsky.social breast nurses, MAs, pharmacists, APPs and oncologists last night! Fills the cup. @marina-sharifi.bsky.social

What a great day at our 2025 retreat- celebrating and socializing with colleagues and planning for the upcoming year. @marina-sharifi.bsky.social @noelleloconte.bsky.social @joshlangmd.bsky.social

Now online in Cancer Discovery: High-Purity Circulating Tumor Cell RNA Sequencing Identifies #ProstateCancer Lineage Phenotypes Prognostic for Clinical Outcomes - by Marina Sharifi, Jamie Sperger, Shuang Zhao, Joshua Lang, and colleagues doi.org/10.1158/2159...

Thanks to the outstanding Heme/Onc and Hospice and Palliative Medicine fellows who are committed to high quality care and ongoing learning! @uwhealth.bsky.social

This work is fundamental to advancing how we diagnose, prevent and treat the diseases the impact all of us. I hope everyone advocates for this funding to be re-instated.

Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists. The statement...

Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...

Grateful to @uwbadgers.bsky.social women’s basketball team for hosting #breastcancer survivors and researchers at the game this weekend!

Moody lab pic of me in a grim piece on this wrecking ball for biomedical research. To explain “indirects": If research is a restaurant, direct costs cover ingredients & cooks' wages. Indirect costs cover kitchen, light & heat, furniture, bookkeeper etc. Lose one, the other follows!
wapo.st/3Q9DrIH

Last but not least, Dr. Sharifi presenting on Genomics/Precision Medicine #SABCS24 abstracts. @uwhealth.bsky.social

What a great day of #SABCS24 @sabcs.bsky.social updates in Wisconsin co-hosted by UWCarbone, MCW and WI Association of Heme/Onc.

Excellent #SABCS updates by Drs. Gradishar and @rmoregan.bsky.social at the 8th (or 10th?) Annual WI conference. Enjoyed catching up and grateful for these mentors and friends.

Dr. Bethany Anderson eloquently presents #SABCS24 radiation abstracts at the WI Best of SABCS. Key theme is individualization based on cancer features and pt preferences. @uwhealth.bsky.social

Dr. Anna Beck from @uwhealth.bsky.social discusses @sabcs.bsky.social surgery abstracts at the WI annual update. Great to see individualization of surgery to de-escalate when appropriate